Decitabine Mesylate – Uses, Dosage, Side Effects, Interaction Decitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of decitabine is as a Nucleic Acid Synthesis Inhibitor. Decitabine is a cytosine analog and an intravenously administered antineoplastic agent used in the therapy of myelodysplastic syndromes. Decitabine is associated with a low rate of transient serum enzyme elevations during therapy but has not been implicated in causing clinically apparent liver injury with jaundice. An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA. Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment options, nucleoside analogs such as decitabine and [azacitidine] integrate into cellular DNA and inhibit the action of DNA methyltransferases, leading to global hypomethylation and related downstream therapeutic benefits. Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. It was first marketed under the name Dacogen®. It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine]. Mechanism of Action Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that manifest in peripheral cytopenias and may eventually progress to secondary acute myeloid leukemia (sAML). Included in the over 45 genes commonly mutated in MDS patients are those involved in DNA methylation and histone modification, and it is well-established that alteration of the epigenetic landscape is a feature of myeloid leukemias. Decitabine is considered a prodrug, as it requires transport into cells and subsequent phosphorylation by distinct kinases to generate the active molecule 5-aza-2′-deoxycytidine-triphosphate, which is incorporated by DNA polymerase during DNA replication. Once incorporated into DNA, decitabine is recognized as a substrate by DNA methyltransferase enzymes (DNMTs), specifically DNMT1, but due to the presence of an N5 rather than C5 atom, traps the DNMT through the irreversible formation of a covalent bond. At low concentrations, this mode of action depletes DNMTs and results in global DNA hypomethylation while at high concentrations, it additionally results in double-strand breaks and cell death. The general hypothesis regarding decitabine’s therapeutic efficacy is that the global hypomethylation it induces results in the expression of previously silent tumour suppressor genes. However, there are other putative mechanisms also related to this change in DNA methylation, including indirect alteration of transcription through effects on transcription factors, indirectly altering histone modifications and chromatin structure, and activating pathways involved in DNA damage response. The overall effect of decitabine is a decrease in neoplastic cell proliferation and an increase in the expression of tumour suppressor genes. Decitabine is a prodrug analogue of the natural nucleotide 2’-deoxycytidine, which, upon being phosphorylated intracellularly, is incorporated into DNA and exerts numerous effects on gene expression. The use of decitabine is associated with neutropenia and thrombocytopenia. In addition, decitabine can cause fetal harm in pregnant women; effective contraception and avoidance of pregnancy are recommended during treatment with decitabine. Indications Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored as belonging to the intermediate-1, intermediate-2, or high-risk group in the International Prognostic Scoring System. Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy. Decitabine is a cytosine analog and an intravenously administered antineoplastic agent used in the therapy of myelodysplastic syndromes. Use In Cancer Decitabine is approved to treat adults with: Myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML). Decitabine is also being studied in the treatment of other conditions and types of cancer. Decitabine is also available in tablet form. Contraindications decreased blood platelets low levels of a type of white blood cell called neutrophils pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: 50 mg Myelodysplastic Syndrome TREATMENT REGIMEN OPTION 1: 15 mg/m2 IV over 3 hours; repeat every 8 hours for 3 days; repeat this cycle every 6 weeks; patients may be premedicated with standard antiemetic therapy If hematologic recovery (ANC 1,000/mcL or greater and platelets 50,000/mcL or greater) from a previous treatment cycle requires more than 6 weeks, then the next cycle should be delayed and dosing temporarily reduced by following this algorithm: Recovery requiring more than 6, but less than 8 weeks: Delay dosing for up to 2 weeks and temporarily reduce the dose to 11 mg/m2 IV every 8 hours (33 mg/m2/day, 99 mg/m2/cycle) when restarting therapy Recovery requiring more than 8, but less than 10 weeks: Assess patient for disease progression (by bone marrow aspirates); in the absence of progression, the dose should be delayed up to 2 more weeks and then reduced to 11 mg/m2 IV every 8 hours (33 mg/m2/day, 99 mg/m2/cycle) when restarting therapy, then maintained or increased in subsequent cycles as clinically indicated TREATMENT REGIMEN OPTION 2: 20 mg/m2 IV over 1 hour; repeat daily for 5 days; repeat this cycle every 4 weeks; patients may be premedicated with standard antiemetic therapy. If myelosuppression is present, subsequent treatment cycles should be delayed until there is hematologic recovery (ANC 1,000/mcL or greater and platelets 50,000/mcL or greater) With either regimen, it is recommended that patients be treated for a minimum of 4 cycles; however, a complete or partial response may take longer than 4 cycles. Perform complete blood and platelet counts prior to each cycle and as needed to monitor response and toxicity. Perform liver chemistries and serum creatinine prior to initiation of therapy. Dose Adjustments If any of the following nonhematologic toxicities are present, decitabine treatment should not be restarted until the toxicity is resolved: 1) serum creatinine greater than or equal to 2 mg/dL; 2) SGPT, total bilirubin greater than or equal to 2 times ULN; and 3) active or uncontrolled infection. Geriatric patients were generally dosed at the same level as younger adult patients. Dose adjustments for toxicity should be conducted as specified for the general population. Administration advice: Once prepared, the final product should be given as a continuous IV infusion over one hour; a central venous catheter is not required. Premedication for the prevention of nausea and vomiting is not typically required but may be administered if necessary. Side Effects The Most Common excessive tiredness pale skin headache dizziness confusion fast heartbeat difficulty falling asleep or staying asleep weakness shortness of breath nausea constipation diarrhea vomiting stomach pain heartburn or indigestion painful sores in the mouth, or on the tongue or lips red spots on the skin rash change in skin color hair loss joint or muscle pain chest discomfort or chest wall pain swelling of the hands, feet, ankles, lower legs, or stomach pain, swelling, or redness at injection spot unusual bleeding or bruising hives itching difficulty breathing or swallowing swelling of the face sore throat, fever, chills, cough, or other signs of infection More Common Black, tarry stools bladder pain bleeding after defecation bleeding gums blood in the urine or stools bloody or cloudy urine blue lips and fingernails blurred vision body aches or pain chest pain chills congestion cough coughing that sometimes produces a pink frothy sputum decreased urination difficult, burning, or painful urination difficult, fast, or noisy breathing dizziness, faintness, or lightheadedness when getting up from a lying or sitting position drowsiness dry mouth or throat fainting fast or irregular heartbeat feeling unusually cold fever flushed, dry skin frequent urge to urinate fruit-like breath odor headache hives or welts, itching, skin rash hoarseness increased hunger increased sweating increased thirst increased urination lightheadedness loss of appetite loss of consciousness lower back or side pain mood or mental changes muscle pain, cramps, spasms, or twitching nausea nervousness numbness or tingling in the hands, feet, or lips pain, redness, swelling, tenderness, or warmth on the skin pale skin pinpoint red spots on the skin redness or pain at the catheter site runny nose seizures shivering small clicking, bubbling, or rattling sounds in the lung when listening with a stethoscope small red or purple spots on the skin, lips or in the mouth sneezing sore mouth, tongue, or throat sores, ulcers, or white spots on the lips or in the mouth stomach pain and bloating sunken eyes swelling of the face, hands, ankles, feet, or lower legs swollen, painful, or tender lymph glands in the neck, armpit, or groin tightness in the chest trembling trouble in swallowing troubled breathing with exertion uncomfortable swelling around the anus unexplained weight loss unusual bleeding or bruising unusual tiredness or weakness voice changes vomiting weakness or heaviness of the legs wrinkled skin yellow eyes or skin Rare Collection of blood under the skin deep, dark purple bruise diarrhea pain or tenderness around the eyes and cheekbones pain, warmth, or burning in the fingers, toes, and legs problems with vision or hearing skin scrape or burn stuffy nose swelling at the injection site muscle stiffness pain in the arms or legs pain in joints stomach discomfort or upset swelling or inflammation of the mouth trouble sleeping unusual drowsiness, dullness, or feeling of sluggishness Difficulty in moving general feeling of discomfort or illness postnasal drip pressure in the stomach swollen joints Drug Interaction DRUG INTERACTION Abatacept The risk or severity of adverse effects can be increased when Decitabine is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Decitabine. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Decitabine. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Decitabine. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Decitabine. Adenovirus type 7 The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Decitabine. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Decitabine. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Decitabine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Decitabine. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Decitabine. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Decitabine. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Decitabine. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Decitabine. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Decitabine. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Decitabine. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Decitabine. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Decitabine. Anifrolumab The risk or severity of adverse effects can be increased when Decitabine is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Decitabine. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Decitabine. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Decitabine. Antilymphocyte The risk or severity of adverse effects can be increased when Decitabine is combined with Antilymphocyte immunoglobulin (horse). Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Decitabine. Antithrombin The risk or severity of bleeding can be increased when Antithrombin III human is combined with Decitabine. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Decitabine. Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Decitabine. Apremilast The risk or severity of adverse effects can be increased when Decitabine is combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Decitabine. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Decitabine. Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Decitabine. Articaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Articaine. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Decitabine. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Decitabine. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Decitabine. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Decitabine. calmette-guerin The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Decitabine. live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Decitabine. Baricitinib The risk or severity of adverse effects can be increased when Decitabine is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Decitabine. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Decitabine. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Decitabine. Belatacept The risk or severity of adverse effects can be increased when Decitabine is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Decitabine is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Decitabine is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Decitabine is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Decitabine. Bendamustine The risk or severity of adverse effects can be increased when Decitabine is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Decitabine. Benzocaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Decitabine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Benzyl alcohol. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Decitabine. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Decitabine. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Decitabine. Bimekizumab The risk or severity of adverse effects can be increased when Decitabine is combined with Bimekizumab. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Decitabine. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Decitabine. Blinatumomab The risk or severity of adverse effects can be increased when Decitabine is combined with Blinatumomab. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Decitabine. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Decitabine. Bosutinib The risk or severity of adverse effects can be increased when Decitabine is combined with Bosutinib. Brentuximab vedotin The risk or severity of adverse effects can be increased when Decitabine is combined with Brentuximab vedotin. Brodalumab The risk or severity of adverse effects can be increased when Decitabine is combined with Brodalumab. Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Decitabine. Bupivacaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Bupivacaine. Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Decitabine. Butacaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Decitabine is combined with Cabazitaxel. Canakinumab The risk or severity of adverse effects can be increased when Decitabine is combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Decitabine. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Decitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Decitabine. Capsaicin The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Capsaicin. Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Decitabine. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Decitabine. Carfilzomib The risk or severity of adverse effects can be increased when Decitabine is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Decitabine. Certolizumab pegol The risk or severity of adverse effects can be increased when Decitabine is combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Decitabine. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Decitabine. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Chloroprocaine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Decitabine. Ciclesonide The risk or severity of adverse effects can be increased when Decitabine is combined with Ciclesonide. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Decitabine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Cinchocaine. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Decitabine. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Decitabine. Clobetasol propionate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Decitabine. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Decitabine. Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Decitabine. Clostridium tetani The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Decitabine. Clozapine The risk or severity of neutropenia can be increased when Decitabine is combined with Clozapine. Cocaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Cocaine. Corticotropin The risk or severity of adverse effects can be increased when Decitabine is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Decitabine is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Decitabine. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Decitabine. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Decitabine. Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Decitabine. Cyclosporine Decitabine may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Decitabine. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Decitabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Decitabine. Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Decitabine. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Decitabine. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Decitabine. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Decitabine. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Decitabine. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Decitabine. Dasatinib The risk or severity of adverse effects can be increased when Dasatinib is combined with Decitabine. Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Decitabine. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Decitabine. Deflazacort The risk or severity of adverse effects can be increased when Decitabine is combined with Deflazacort. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Decitabine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Decitabine. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Decitabine. Deucravacitinib The risk or severity of adverse effects can be increased when Decitabine is combined with Deucravacitinib. Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Decitabine. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Decitabine. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Decitabine. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Decitabine. Difluocortolone The risk or severity of adverse effects can be increased when Decitabine is combined with Difluocortolone. Dimethyl fumarate The risk or severity of adverse effects can be increased when Decitabine is combined with Dimethyl fumarate. Dinutuximab The risk or severity of adverse effects can be increased when Decitabine is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Decitabine. Diroximel fumarate The risk or severity of adverse effects can be increased when Decitabine is combined with Diroximel fumarate. Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Decitabine. Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Decitabine. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Decitabine. Dyclonine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Dyclonine. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Decitabine. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Decitabine. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Decitabine. Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Decitabine. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Decitabine. Emapalumab The risk or severity of adverse effects can be increased when Decitabine is combined with Emapalumab. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Decitabine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Decitabine. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Decitabine. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Decitabine. Eribulin The risk or severity of adverse effects can be increased when Decitabine is combined with Eribulin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Decitabine. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Decitabine. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Decitabine. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Etidocaine. Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Decitabine. Everolimus The risk or severity of adverse effects can be increased when Decitabine is combined with Everolimus. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Decitabine. Filgotinib The risk or severity of adverse effects can be increased when Decitabine is combined with Filgotinib. Fingolimod Decitabine may increase the immunosuppressive activities of Fingolimod. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Decitabine. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Decitabine. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Decitabine. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Decitabine. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Decitabine. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Decitabine. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Decitabine. Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Decitabine. Fluocortolone The risk or severity of adverse effects can be increased when Decitabine is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Decitabine. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Decitabine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Decitabine. Fluprednisolone The risk or severity of adverse effects can be increased when Decitabine is combined with Fluprednisolone. Fluticasone The risk or severity of adverse effects can be increased when Decitabine is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Decitabine is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Decitabine. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Decitabine. Gallium nitrate The risk or severity of adverse effects can be increased when Decitabine is combined with Gallium nitrate. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Decitabine. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Decitabine. Glatiramer The risk or severity of adverse effects can be increased when Decitabine is combined with Glatiramer. Golimumab The risk or severity of adverse effects can be increased when Decitabine is combined with Golimumab. Guselkumab The risk or severity of adverse effects can be increased when Decitabine is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Decitabine. Heparin The risk or severity of bleeding can be increased when Heparin is combined with Decitabine. Hepatitis A The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Decitabine. Hepatitis B The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Decitabine. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Decitabine. Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Decitabine. Hydrocortisone acetate The risk or severity of adverse effects can be increased when Decitabine is combined with Hydrocortisone acetate. Hydrocortisone butyrate The risk or severity of adverse effects can be increased when Decitabine is combined with Hydrocortisone butyrate. Hydrocortisone succinate The risk or severity of adverse effects can be increased when Decitabine is combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Decitabine. Hydroxychloroquine The risk or severity of adverse effects can be increased when Decitabine is combined with Hydroxychloroquine. Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Decitabine. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Decitabine. Ibrutinib The risk or severity of adverse effects can be increased when Decitabine is combined with Ibrutinib. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Decitabine. Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Decitabine. Idelalisib The risk or severity of adverse effects can be increased when Decitabine is combined with Idelalisib. Ifosfamide The risk or severity of adverse effects can be increased when Ifosfamide is combined with Decitabine. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Decitabine. Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Decitabine. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Decitabine. Inebilizumab The risk or severity of infection can be increased when Decitabine is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Decitabine. Leflunomide The risk or severity of adverse effects can be increased when Decitabine is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Decitabine. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Decitabine. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Levobupivacaine. Lidocaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Lidocaine. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Decitabine. Lipegfilgrastim Decitabine may increase the myelosuppressive activities of Lipegfilgrastim. Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Decitabine. Lopinavir The serum concentration of Decitabine can be increased when it is combined with Lopinavir. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Decitabine. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Decitabine. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Decitabine. Meloxicam The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Decitabine. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Decitabine. Mepivacaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Decitabine is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Decitabine is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Decitabine. Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Decitabine. Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Decitabine. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Decitabine. Methoxy poly The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Decitabine. Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Decitabine. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Decitabine. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Decitabine. COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Decitabine. Modified vaccinia The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Decitabine. Mometasone furoate The risk or severity of adverse effects can be increased when Decitabine is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Decitabine is combined with Monomethyl fumarate. Mosunetuzumab The risk or severity of adverse effects can be increased when Decitabine is combined with Mosunetuzumab. Mumps virus strain The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Decitabine. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Decitabine. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Decitabine. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Decitabine. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Decitabine. Natalizumab The risk or severity of adverse effects can be increased when Decitabine is combined with Natalizumab. Nelarabine The risk or severity of adverse effects can be increased when Decitabine is combined with Nelarabine. Nilotinib The risk or severity of adverse effects can be increased when Decitabine is combined with Nilotinib. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Decitabine. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Decitabine. Obinutuzumab The risk or severity of adverse effects can be increased when Decitabine is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Decitabine. Ofatumumab The risk or severity of adverse effects can be increased when Decitabine is combined with Ofatumumab. Olaparib The risk or severity of adverse effects can be increased when Decitabine is combined with Olaparib. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Decitabine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Oxybuprocaine. Ozanimod The risk or severity of adverse effects can be increased when Decitabine is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Decitabine. Palbociclib The risk or severity of adverse effects can be increased when Decitabine is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Decitabine. Panobinostat The risk or severity of adverse effects can be increased when Decitabine is combined with Panobinostat. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Decitabine. Pazopanib The risk or severity of adverse effects can be increased when Decitabine is combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Decitabine. Pegcetacoplan The risk or severity of adverse effects can be increased when Decitabine is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Decitabine. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Decitabine. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Decitabine. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Decitabine is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Decitabine. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Decitabine. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Decitabine. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Decitabine. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Decitabine. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Decitabine. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Decitabine. Phenol The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Phenol. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Decitabine. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Decitabine. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Decitabine. Pirfenidone The risk or severity of adverse effects can be increased when Decitabine is combined with Pirfenidone. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Decitabine. Pomalidomide The risk or severity of adverse effects can be increased when Decitabine is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Decitabine is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Decitabine is combined with Ponesimod. Pralatrexate The risk or severity of adverse effects can be increased when Decitabine is combined with Pralatrexate. Pramocaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Decitabine. Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Decitabine. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Decitabine. Prilocaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Decitabine. Proparacaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Propoxycaine. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Decitabine. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Decitabine. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Decitabine. Rabies immune globulin The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Decitabine. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Decitabine. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Decitabine. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Decitabine. Ravulizumab The risk or severity of adverse effects can be increased when Decitabine is combined with Ravulizumab. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Decitabine. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Decitabine. Rilonacept The risk or severity of adverse effects can be increased when Decitabine is combined with Rilonacept. Risankizumab The risk or severity of adverse effects can be increased when Decitabine is combined with Risankizumab. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Decitabine. Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Decitabine. Roflumilast Roflumilast may increase the immunosuppressive activities of Decitabine. Ropeginterferon The risk or severity of adverse effects can be increased when Decitabine is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Ropivacaine. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Decitabine. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Decitabine. Ruxolitinib The risk or severity of adverse effects can be increased when Decitabine is combined with Ruxolitinib. Sarilumab The risk or severity of adverse effects can be increased when Decitabine is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Decitabine is combined with Satralizumab. Secukinumab The risk or severity of adverse effects can be increased when Decitabine is combined with Secukinumab. Siltuximab The risk or severity of adverse effects can be increased when Decitabine is combined with Siltuximab. Siponimod The risk or severity of adverse effects can be increased when Decitabine is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Decitabine. Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Decitabine. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Decitabine. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Decitabine. Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Decitabine. Spesolimab The risk or severity of adverse effects can be increased when Decitabine is combined with Spesolimab. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Decitabine. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Decitabine. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Decitabine. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Decitabine. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Decitabine. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Decitabine. Sunitinib The risk or severity of adverse effects can be increased when Decitabine is combined with Sunitinib. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Decitabine. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Decitabine is combined with Tedizolid phosphate. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Decitabine. Temsirolimus The risk or severity of adverse effects can be increased when Decitabine is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Decitabine. Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Decitabine. Teprotumumab The risk or severity of adverse effects can be increased when Decitabine is combined with Teprotumumab. Teriflunomide The risk or severity of adverse effects can be increased when Decitabine is combined with Teriflunomide. Tetracaine The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Tetracaine. Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Decitabine. Thiotepa The risk or severity of adverse effects can be increased when Decitabine is combined with Thiotepa. Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Decitabine. Tick encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Decitabine. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Decitabine. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Decitabine. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Decitabine. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Decitabine. Tixocortol The risk or severity of adverse effects can be increased when Decitabine is combined with Tixocortol. Tocilizumab The risk or severity of adverse effects can be increased when Decitabine is combined with Tocilizumab. Tofacitinib Decitabine may increase the immunosuppressive activities of Tofacitinib. Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Decitabine. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Decitabine. Trabectedin The risk or severity of adverse effects can be increased when Decitabine is combined with Trabectedin. Trastuzumab Trastuzumab may increase the neutropenic activities of Decitabine. Trastuzumab The risk or severity of adverse effects can be increased when Decitabine is combined with Trastuzumab emtansine. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Decitabine. Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Decitabine. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Decitabine. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Decitabine. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Decitabine. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Decitabine. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Decitabine. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Decitabine. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Decitabine. Upadacitinib The risk or severity of adverse effects can be increased when Decitabine is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Decitabine. Varicella zoster vaccine The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Decitabine. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Decitabine. Vedolizumab The risk or severity of adverse effects can be increased when Decitabine is combined with Vedolizumab. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Decitabine. Vilanterol The risk or severity of adverse effects can be increased when Decitabine is combined with Vilanterol. Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Decitabine. Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Decitabine. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Decitabine. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Decitabine. Voclosporin The risk or severity of adverse effects can be increased when Decitabine is combined with Voclosporin. Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Decitabine. Vorinostat The risk or severity of adverse effects can be increased when Decitabine is combined with Vorinostat. Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Decitabine. Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Decitabine. Yellow fever vaccine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Decitabine. Pregnancy And Lactation US FDA pregnancy category Not Assigned Pregnancy If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant while being treated with this drug. The period following therapy when it is safe to become pregnant is unknown. Men should use effective contraception and be advised to not father a child while receiving this drug, and for 3 months following the last dose. Lactation There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. How Should This Medicine Be Used? Decitabine comes as a powder to be to be added to fluid and injected slowly over 3 hours intravenously (into a vein) by a doctor or nurse in a medical office or hospital outpatient clinic. It is usually injected every 8 hours for 3 days. This treatment period is called a cycle, and the cycle may be repeated every 6 weeks for as long as your doctor recommends. Decitabine should usually be given for at least four cycles but may be continued if your doctor decides that you will benefit from additional treatment. Your doctor may also need to delay your treatment and reduce your dose if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with decitabine. Your doctor will give you medication to prevent nausea and vomiting before you receive each dose of decitabine. What Special Precautions Should I Follow? Before receiving a dose of decitabine, tell your doctor and pharmacist if you are allergic to decitabine or any other medications. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have kidney or liver disease. tell your doctor if you are pregnant or plan to become pregnant, or if you plan to father a child. You or your partner should not become pregnant while you are using decitabine. You should use birth control to prevent pregnancy in yourself or your partner during your treatment with decitabine and for 2 months afterward. Talk to your doctor about birth control methods that will work for you. If you or your partner becomes pregnant while using decitabine, call your doctor. Decitabine may harm the fetus. tell your doctor if you are breastfeeding. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021790s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021790lbl.pdf https://pubchem.ncbi.nlm.nih.gov/compound/Decitabine https://pubchem.ncbi.nlm.nih.gov/compound/Decitabine-mesylate https://www.cancer.gov/about-cancer/treatment/drugs/decitabine https://medlineplus.gov/druginfo/meds/a608009.html https://go.drugbank.com/drugs/DB01262 https://en.wikipedia.org/wiki/Decitabine https://www.drugs.com/mtm/decitabine.html CAMEO Chemicals https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false 5-AZA-2′-DEOXYCYTIDINE https://cameochemicals.noaa.gov/chemical/19836 CAMEO Chemical Reactivity Classification https://cameochemicals.noaa.gov/browse/react CAS Common Chemistry https://creativecommons.org/licenses/by-nc/4.0/ 5-Aza-2′-deoxycytidine https://commonchemistry.cas.org/detail?cas_rn=2353-33-5 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Decitabine [USAN:INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0002353335 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DrugBank https://www.drugbank.ca/legal/terms_of_use Decitabine https://www.drugbank.ca/drugs/DB01262 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Decitabine https://comptox.epa.gov/dashboard/DTXSID7030432 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one https://echa.europa.eu/substance-information/-/substanceinfo/100.017.355 1-(2-Deoxy-a-D-ribofuranosyl)-5-azacytosine https://echa.europa.eu/information-on-chemicals 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/12514 1-(2-Deoxy-a-D-ribofuranosyl)-5-azacytosine https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/257831 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking DECITABINE https://gsrs.ncats.nih.gov/ginas/app/beta/substances/776B62CQ27 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Decitabine http://www.hmdb.ca/metabolites/HMDB0015391 ChEBI 5-aza-2′-deoxycytidine http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50131 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking DECITABINE https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Decitabine https://www.ncbi.nlm.nih.gov/books/n/livertox/Decitabine/ ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201129/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp Decitabine https://ctdbase.org/detail.go?type=chem&acc=D000077209 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads DECITABINE https://www.dgidb.org/drugs/DECITABINE Therapeutic Target Database (TTD) Decitabine http://idrblab.net/ttd/data/drug/details/D0X5XU ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html DECITABINE https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=DECITABINE CEDAZURIDINE; DECITABINE https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CEDAZURIDINE;+DECITABINE Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking decitabine https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Dacogen (EMEA/H/C/002221) https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book NORMAN Suspect List Exchange https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking DECITABINE https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Dacogen (Decitabine) https://www.cancer.gov/about-cancer/treatment/drugs/decitabine NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html decitabine https://rxnav.nlm.nih.gov/id/rxnorm/15657 PubChem https://pubchem.ncbi.nlm.nih.gov SpectraBase 5-Aza-2′-deoxycytidine https://spectrabase.com/spectrum/AkBF81zsyms 5-Aza-2′-Deoxycytidine https://spectrabase.com/spectrum/4StDPPSfTsB Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=16047535-401683533 https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=16047535-401771294 Thieme Chemistry LICENSE https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=16047535-4017897 Wikidata https://creativecommons.org/publicdomain/zero/1.0/ Decitabine https://www.wikidata.org/wiki/Q1181878 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Decitabine https://www.ncbi.nlm.nih.gov/mesh/2027933 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Enzyme Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68004791 Antimetabolites, Antineoplastic https://www.ncbi.nlm.nih.gov/mesh/68000964 KEGG https://www.kegg.jp/kegg/legal.html USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg Drug Classes http://www.genome.jp/kegg-bin/get_htext?br08332.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html PATENTSCOPE (WIPO) SID 388661603 https://pubchem.ncbi.nlm.nih.gov/substance/388661603 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More You Might Also Read Ramipril; Uses, Dosage, Side Effects, Interactions, Pregnancy